WallStSmart

AstraZeneca PLC (AZN)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 596314% more annual revenue ($58.74B vs $9.85M). AZN leads profitability with a 17.4% profit margin vs -10.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

WOK

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$187.37

$27.14 discount

UndervaluedFair: $214.51Overvalued

Intrinsic value data unavailable for WOK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

WOK1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

WOK4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Market CapQuality
$1.56M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

Revenue GrowthGrowth
-14.4%2/10

Revenue declined 14.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bull Case : WOK

The strongest argument for WOK centers on Price/Book.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : WOK

The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.

Key Dynamics to Monitor

AZN profiles as a value stock while WOK is a turnaround play — different risk/reward profiles.

AZN is growing revenue faster at 4.1% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (64/100 vs 29/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

WORK Medical Technology Group LTD Ordinary Shares

HEALTHCARE · MEDICAL DEVICES · USA

WORK Medical Technology Group Ltd is a leading entity in the medical technology sector, dedicated to the research, development, and commercialization of cutting-edge healthcare solutions. The company specializes in advanced medical devices designed to enhance patient outcomes and address critical challenges in global healthcare. Its commitment to quality and innovation, combined with a diverse product portfolio, positions WORK for sustained growth, making it an attractive investment opportunity for institutional investors seeking to engage in transformative advancements within the healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?